Author

Geert R. D'Haens 1

1 Robarts Clinical Trials Inc.,London,Canada

AN EXPERT CONSENSUS TO STANDARDIZE THE ASSESSMENT OF HISTOLOGIC DISEASE ACTIVITY IN CROHN'S DISEASE CLINICAL TRIALS

Ahmed Almradi, Christopher Ma, Geert R. D'Haens, William Sandborn, Claire Parker, Leonardo Guizzetti, Paula Borralho Nunes, Geert De Hertogh, Roger M. Feakins, Reena Khanna, Gregory Y. Lauwers, Aart Mookhoek, Reet Pai, Laurent Peyrin-Biroulet, Robert Riddell, Christophe Rosty, David F. Schaeffer, Mark Valasek, Brian G. Fe

association between serum and tissue protein profiles in patients with inflammatory bowel disease: the ascertain study

Toer W. Stevens, Matic Koželj, Gregor Novak, Krisztina Barbara Gecse, Marjolijn Duijvestein, Mark Lowenberg, Manon E. Wildenberg, David Drobne, Geert R. D'Haens

Biologic Use in Adult Patients Newly Diagnosed with Crohn's Disease in the United States, 2010-2013 and 2014-2016

Geert R. D'Haens, April Naegeli, Malika Mahoui, Stuart Morton, Yan Dong, Theresa Hunter, Mallory Farrar, James Canavan, Diana Stefani-Hunyady

Biologic Use in Adult Patients Newly Diagnosed with Ulcerative Colitis in the United States, 2010-2013 and 2014-2016

Geert R. D'Haens, April Naegeli, Malika Mahoui, Stuart Morton, Yan Dong, Theresa Hunter, Mallory Farrar, James Canavan, Diana Stefani-Hunyady

CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

Silvio Danese, Severine Vermeire, Geert R. D'Haens, Julian Panés, Axel Dignass, Fernando Jose Magro Dias, Maciek Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Fréderic Lavie, Ivana Bravata, Sheldon Sloan, Marco Daperno, Milan Lukas, Alessandro Armuzzi, Mark Lowenberg, Daniel R. Gaya, Laurent Peyrin-Biroulet

Clinical Remission Demonstrated with Oral Ozanimod in the Overall Population and Across Multiple Subgroups of Patients with Moderately to Severely Active Ulcerative Colitis in the TOUCHSTONE Trial

Brian G. Feagan, William Sandborn, Geert R. D'Haens, Steve Hanauer, Douglas C. Wolf, Severine Vermeire, Subrata Ghosh, Annkatrin Petersen Jappelli, Steven Ye Hua, Kevin Shan, W Jerry Liu

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Silvio Danese, William Sandborn, Edward V. Loftus Jr., Stephen B Hanauer, Stefan Schreiber, Laurent Peyrin-Biroulet, Remo Panaccione, Julian Panés, Filip Baert, Jean-Frederic Colombel, Marc Ferrante, Edouard Louis, Alessandro Armuzzi, Sasikiran Goteti, John Liu, Nael M. Mostafa, Thao Doan, Joel Petersson, Anne M. Robinson

Combined endoscopic and histological healing with vedolizumab in therapy-refractory Crohn's disease, data from the LOVE-CD trial

Mark Lowenberg, Nahid Mostafavi, Severine Vermeire, Frank Hoentjen, C. Ambarus, Esmé Clasquin, Filip Baert, Geert R. D'Haens

COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY

Geert R. D'Haens

COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY

Geert R. D'Haens, Julian Panés, Edouard Louis, Qian Zhou, John Liu, Ana P. Lacerda, Edward Loftus

Item 1 - 10 / 36
1
2 3 4